Loading stock data…
ARVN
$10.51+0.61 (+6.16%)
Market ClosedLast close May 1
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Arvinas, Inc. in the Healthcare sector is trading at $10.51. The stock is currently 28% below its 52-week high of $14.51, remaining 0.6% above its 200-day moving average. Technical signals show neutral RSI of 49 and bearish MACD signal, explaining why ARVN maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 49) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$10.51
Potential Upside
5%
Whystock Fair Value$11.04
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus16 analysts
Buy
Mean target$14.88+41.5%
Range$6.00 – $21.00
Fundamentals
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degrad...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$682.70M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.98
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-16.74%
Volume
Today's trading volume
2.15M
Recent News
Arvinas’ ‘Protac’ breast cancer drug cleared by FDA
Known as Veppanu, the drug is the first of its kind to get to market. But Arvinas and partner Pfizer are still searching for a new partner to sell it.
How The Arvinas (ARVN) Story Is Evolving As 2026 Neurology Catalysts Approach
The Arvinas fair value estimate has shifted from US$14.56 to US$14.88 per share, a small move that still matters if you are tracking valuation updates closely. Street research ties this change to refreshed views after the Q4 update, including new milestones in the neurology pipeline and a split between more optimistic and more cautious price targets that now cluster roughly between US$11 and US$20. As you read on, you will see how to interpret these revisions and keep up with the evolving...
Arvinas (ARVN) Moves 6.9% Higher: Will This Strength Last?
Arvinas (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Arvinas Highlights Phase 1 Shift, 2026 Data Catalysts, and Vepdegestrant NDA at Barclays Conference
Arvinas (NASDAQ:ARVN) executives outlined a portfolio shift toward early-stage development and previewed multiple clinical catalysts in a discussion hosted by Barclays biotech analyst Esra Darroudi. Chief Executive Officer Randy Teel and Chief Scientific Officer Angela Cacace said the company is ent
Arvinas Teases Near-Term Phase 1 Data, Eyes New Vepdegestrant Partner at Leerink Conference
Executives from Arvinas (NASDAQ:ARVN) outlined the company’s clinical pipeline and near-term milestones during a presentation at Leerink Partners’ Global Healthcare Conference, emphasizing multiple Phase 1 programs expected to generate data over the coming year. Company overview and focus on clinic